| Detected | Trial | Change |
|---|---|---|
| 2026-08-12 | NCT06162572 Phase 1b/2 Platform Study of Select Immunotherapy Combinations in Participants With… |
Trial sites reduced: 63 -> 56 locations |
| NCT ID | Title | Condition | Status |
|---|---|---|---|
| Phase 3 | |||
| NCT06127407 | Ivosidenib in Participants With Locally Advanced or Metastatic Conventional… | Locally Advanced or Metastatic Conventional Chondrosarcoma With an IDH1 Mutation, Untreated or Previously Treated With 1 Systemic Treatment Regimen | Recruiting |
| Phase 1/2 | |||
| NCT06116136 | A Study to Evaluate the Safety and the Activity of S095029 as Part of Combination Therapy… | MSI-H/dMMR Gastroesophageal-junction Cancer | Active, Not Recruiting |
| NCT06188702 | S095035 as a Single Agent and in Combination in Adult Participants With Advanced or… | MTAP-deleted Solid Tumors | Active, Not Recruiting |
| NCT06162572 | Phase 1b/2 Platform Study of Select Immunotherapy Combinations in Participants With… | Non-small Cell Lung Cancer (NSCLC) | Active, Not Recruiting |
| Phase 1 | |||
| NCT07006688 | A Study of an IDH1m Inhibitor in Participants With IDH1-Mutated Malignancies and Hepatic… | IDH1-Mutated Malignancies | Recruiting |